Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
EMPOWER: Sarilumab + Capecitabine in TNBC
NCT04333706Phase 2Recruiting
- Sponsor
- University of Southern California
- Start
- Sep 2020
- Primary completion
- Nov 2026
- Modality
- Recombinant Proteins and Enzymes, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of sarilumab in triple-negative breast cancer (TNBC), sponsored by University of Southern California. Started Sep 2020; status: recruiting.
02
Drugs
sarilumab
03
Conditions
triple-negative breast cancer (TNBC)
Beyond the preview
Go deeper on NCT04333706.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04333706.